And I think there is a strong reason why LC kept mentioning and comparing Her-Vaxx to Herceptin. I would not be surprised if Roche has already given an indication to IMU. After all, Roche will stand to lose the most in this space. And yet, Roche is the one who made money from their investment in Herceptin. So to stay ahead of the pack, it is only logical they re-invest the profit from Herceptin into Her-Vaxx. And the way LC bandied that $7-8bn figure around, I wonder if that would be the rough initial down payment for an exclusive licence to market our B-cell technology with an ongoing royalty to IMU.
If that should come to pass, what more need I say?
-
- There are more pages in this discussion • 1,166 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
-0.001(7.14%) |
Mkt cap ! $97.07M | |||
| Open | High | Low | Value | Volume |
| 1.4¢ | 1.4¢ | 1.3¢ | $150.5K | 10.89M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 81 | 18980079 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 6177126 | 16 |
View Market Depth
| Last trade - 13.23pm 18/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |